Search results
Results from the WOW.Com Content Network
Myelosupression, embryo-fetal toxicity, hepatotoxicity (rare) [19] Trabectedin: IV Alkylates DNA. Advanced liposarcoma and leimyosarcoma Bone marrow suppression, rhabdomyolysis, embryo-fetal toxicity, capillary leak syndrome, hepatotoxicity [20] 1.10 Platinum compounds: Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Acute radiation syndrome (ARS), also known as radiation sickness or radiation poisoning, is a collection of health effects that are caused by being exposed to high amounts of ionizing radiation in a short period of time. [1] Symptoms can start within an hour of exposure, and can last for several months.
Pulmonary toxicity is the medical name for side effects on the lungs. Although most cases of pulmonary toxicity in medicine are due to side effects of medicinal drugs, many cases can be due to side effects of radiation (radiotherapy). Other (non-medical) causes of pulmonary toxicity can be chemical compounds and airborne particulate matter.
Analgesics or painkillers are defined as medications that help to manage and reduce pain. It is often used in treatments of arthritis to provide relief on the site of injury. Acetaminophen, opioids and counterirritants are common analgesics used in the therapy of arthritis. However, these drugs have no control over inflammation. [25]
Nplate, manufactured by U.S. drugmaker Amgen, was approved by the Food and Drug Administration in 2021 to treat injuries caused by acute radiation syndrome, also known as radiation sickness.
A set of radioimmunotherapy drugs that rely upon an alpha-emitting isotope (e.g., bismuth-213 or, preferably, actinium-225), rather than a beta emitter, as the killing source of radiation is being developed. Several phase II clinical trials for the treatment of acute myeloid leukemia have been carried out using alpha-emitting RITs. [10] [11]
The worry is that some high-dose treatments may be limited by the radiation toxicity capacity of healthy tissues which lie close to the target tumor volume. An example of this problem is seen in radiation of the prostate gland, where the sensitivity of the adjacent rectum limited the dose which could be safely prescribed using 2DXRT planning to ...